The guidelines include recommendations for first-, second-, and third-line therapy. The American Society of Clinical Oncology (ASCO) has updated its guidelines on the use of systemic therapy for ...

Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...

Only patients with advanced hepatocellular carcinoma (HCC) and preserved liver function should receive systemic therapies, according to new clinical practice guidelines from the American ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

CHICAGO--(BUSINESS WIRE)--New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer. CEUS is a ...

Survival of Trial-Like and Non–Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP) Hepatocellular carcinoma (HCC ...

Since 1980, the incidence of hepatocellular carcinoma (HCC) has tripled in the United States. The uptick in this deadly liver cancer was thankfully accompanied by the introduction of new and improved ...

Please provide your email address to receive an email when new articles are posted on . “[The paper] doesn’t address all the treatments; it just addresses a very specific set of treatments. We were ...